- Tucked in its Q3 earnings release on Monday afternoon, Surrozen Inc (NASDAQ:SRZN) voluntarily paused enrollment in the single ascending dose (SAD) portion of its Phase 1 trial evaluating SZN-1326 in healthy volunteers following the observation of treatment-related adverse events.
- SZN-1326 is a Wnt mimetic bi-specific antibody that selectively activates the Wnt pathway and is in development for ulcerative colitis.
- Several subjects experienced asymptomatic liver transaminase elevations (elevated liver enzymes), including three subjects with grade 3 ALT and AST elevations.
- Related: Surrozen Inks Strategic Partnership With Boehringer Ingelheim For Retinal Disease Candidate.
- Elevated levels of either of these enzymes are potential indicators of liver damage or liver disease.
- There were no corresponding increases in total bilirubin nor any changes in liver function markers such as coagulation markers or albumin.
- No other clinically significant laboratory abnormalities were observed, and the transaminase elevations resolved spontaneously in all subjects.
- No serious adverse events were observed during the study.
- Price Action: SRZN shares closed 30.2% lower at $1.25 on Tuesday.
United Microelectronics Corp Clocks 19% YoY Sales Decline In April 2023 And 16% YoY Decline During January-April
United Microelectronics Corporation (NYSE:UMC, TWSE: 2303)))) ("UMC"), today reported unaudited net sales for the month of April 2023.
Revenues for April
